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The development of various types of cancer results from the interaction among endogenous, environmen-
tal and hormonal factors, where the most notable of these factors is diet. The aim of the present study was
to determine the antigenotoxic, anticarcinogenic, phagocytic and immunomodulatory activities of Agar-
icus blazei. The test antigenotoxicity (Comet Assay) and anticarcinogenic (Test of Aberrant Crypt Foci)
assess changes in DNA and/or intestinal mucosa that correlate to cancer development. Tests of phagocy-
tosis in the spleen and differential count in blood cells allow the inference of modulation of the immune
system as well as to propose a way of eliminating cells with DNA damage. Supplementation with the
mushroom was carried out under pre-treatment, simultaneous treatment, post-treatment and pre-treat-
ment + continuous conditions. Statistical analysis demonstrated that the mushroom did not have geno-
toxic activity but showed antigenotoxic activity. Supplementation caused an increase in the number of
monocytes and in phagocytic activity, suggesting that supplementation increases a proliferation of
monocytes, consequently increasing phagocytic capacity especially in the groups pre-treatment, simulta-
neous and pre-treatment + continuous. The data suggest that A. blazei could act as a functional food capa-
ble of promoting immunomodulation which can account for the destruction of cells with DNA alterations
that correlate with the development of cancer, since this mushroom was demonstrated to have a preven-
tive effect against pre-neoplastic colorectal lesions evaluated by the aberrant crypt foci assay. According
to these results and the literature, it is believed that supplementation with A. blazei can be an efﬁcient
method for the prevention of cancer as well as possibly being an important coadjuvant treatment in
chemotherapy.
 2011 Elsevier Inc. Open access under the Elsevier OA license.1. Introduction paper). The nutritional state together with the condition of theIn Brazil, cancer represents the second leading cause of death in
the adult population. And the most common cancers in the Brazil-
ian population is melanoma skin cancer, followed by tumors of the
breast, prostate, lung, colon and rectum, stomach and cervix (INCA,
2008).
Diet represents the greatest interaction of humans with the
environment. All foods that are ingested or nutrients that are ab-
sorbed can have a beneﬁcial potential or present a risk to systemic
pathologies and of gastrointestinal tract (object of study in thise Nutrição – Centro Univer-
, 86600-000 Rolândia – PR,
sevier OA license.body can prevent or help ﬁght disease, or inversely, can cause a
greater susceptibility to disease (Hesketh et al., 2006).
The regular consumption of functional foods reduces the risk of
various chronic diseases, mainly cardiovascular, cancer, diabetes,
hypertension and osteoporosis (Hornstra et al., 1998; López-Varela
et al., 2002).
Agaricus blazei is known in Brazil as the sun mushroom, in Japan
as himematsutake, agarikusutake or kawarihiratake and in China
as Ji Song Rong. It was brought from Japan due to its beneﬁcial
health effects, like prevention of diabetes, hyperlipidemia, arterio-
sclerosis and chronic hepatitis (Takaku et al., 2010). Nowadays, it is
widely utilized in Oriental countries as an edible mushroom. Con-
sidered as a functional food (functional food is a part of an every-
day diet and is demonstrated to offer health beneﬁts and to reduce
the risk of chronic disease beyond the widely accepted nutritional
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medicinal extract for the prevention and treatment of cancer
(Firenzuoli et al., 2007).
In general, the total composition of the mushrooms is water
(90%), protein (2–40%), carbohydrates (1–55%), ﬁber (3–32%) and
ash (8–10%). The ash content is made upmainly of salts, metals like
calcium and magnesium (Firenzuoli et al., 2007). Among the carbo-
hydrates are notably some biologically active polysaccharides,
present in the basidiocarp and/or mycelium, such as the b-glucans
which have attracted the attention of investigators (Mizuno, 1995).
b-Glucans consist of units of D-glucopyranosyl and its structure de-
pends on the source and methods of extraction utilized. b-Glucans
extracted from the mushroom A. blazei have a structure principally
formed by chains of D-glucose with b(1? 3) linkages and branch-
ing with b(1? 6) connections (Angeli et al., 2008).
Immunotherapy in utilized in many cancer patients, improving
their quality of life, and is also an important form of adjuvant treat-
ment (Ohno et al., 1999). Besides immunomodulatory capacity,
antimutagenic, antigenotoxic, antitumor and antiteratogenic activ-
ities have also been described for A. blazei and different b-glucans
(Di Luzio et al., 1979; Grüter et al., 1991; Saitô et al., 1991;
Demleitner et al., 1992; Kishida et al., 1992; Chorvatovicová
et al., 1996, 1999; Lohman et al., 2001; Slamenová et al., 2003;
Tohamy et al., 2003; Lin et al., 2004; Oliveira et al., 2009).
Based on the above ﬁndings, the aim of the present study was to
determine the antigenotoxic, anticarcinogenic, phagocytic and
immunomodulatory activities of the mushroom A. blazei in Swiss
mice.2. Material and methods
2.1. Chemical agents
DNA damage was induced using 1,2-dimethylhydrazine (DMH;
Sigma, CAS No. 306-37-6) at a concentration of 20 mg/kg body
weight (b.w.) diluted in EDTA solution (37 mg/mL) and adminis-
tered to the animals intraperitoneal (i.p). The applications were
according to the protocol proposed by Silva (1999), in which four
doses of DMH were administered, where two doses per week were
given for 2 weeks.
2.2. Preparation of diet and supplementation
The mushroom A. blazei was supplied by Prof. Dr. Mario Sergio
Mantovani of the Genetic Toxicology Laboratory, Biological Sci-
ences Center, Department of General Biology, State University of
Londrina – UEL, Londrina, PR, Brazil. The commercial ration
Nuvilab was ground and the dried mushroom, also ground, was
added at a proportion of 10%. The components were then mixed,
moistened and pelletized, and the pellets were then dried in an
oven at 40 C. The concentration of A. blazei was deﬁned according
to Nosál’ová et al. (2001). The ration was offered to the animals
every day, but amounts (100–150 g/day); otherwise, because of
palatability, the mice tended to nibble at the ration without
ingesting it.
2.3. Animals and experimental design
Male Swiss mice at reproductive age were used for the study;
they were about 60 days old, with a mean weight of 30 g, and were
from the Center for the Study of Nutrition and Genetic Toxicology –
CENUGEN of the Centro Universitario Filadelﬁa – UniFil, Londrina,
PR, Brazil. The experiments were conducted in the center’s animal
facility. Two experiments were conducted where the ﬁrst deter-
mined antigenotoxicity, phagocytic activity and differential bloodcell counts, and the second entailed the aberrant crypt foci assay.
In the ﬁrst experiment, the animals were divided into 7 experi-
mental groups with 7 animals/group. However, in the second
experiment the number of groups was the same but with 11 ani-
mals/group. The animals were kept in propylene cages lined with
wood shavings which were changed daily. The animals spent a
minimum acclimation period of seven days. Light and temperature
were controlled using a 12-h photoperiod (12 h dark: 12 h light)
with the temperature kept at 22 ± 2 C and humidity at 55 ± 10%.
Feeding was ad libitum and consisted of ﬁltered water and com-
mercial ration supplemented or not with 10% A. blazei, according
to the experimental groups.
The experiment was performed according to the guidelines of
the Brazilian College of Animal Experimentation (COBEA, 2004)
and approved by the Committee of Ethics in Animal Experimenta-
tion of the State University of Londrina.
2.3.1. Experiment 1
The animals were treated for 4 weeks, the experimental groups
are as follows: Control Group (EDTA-solution in which the DMH
was diluted) – the animals were maintained for 2 weeks, receiving
only commercial ration and ﬁltered water. In the 3rd and 4th
weeks of the experiment, they were given EDTA solution (0.1 ml/
10 g b.w., i.p.), two times per week, together with commercial ra-
tion, everyday of this period; Group DMH – the animals were sub-
mitted to the same situations as in the control group; however,
EDTA was substituted by DMH at a dose of 20 mg/kg b.w. (i.p.);
Group A. blazei – the animals were offered ration supplemented
with A. blazei at a proportion of 10% during the entire experimental
period (4 weeks); the other procedures were performed as de-
scribed for the control group; Group pre-treatment – the animals
received for the ﬁrst 2 weeks of the experiment ration supple-
mented with A. blazei. After the end of this period, the administra-
tion of 4 doses of DMH (20 mg/kg b.w., i.p.) was begun, where 2
doses were given in the 3rd and the other 2 doses in the 4th week;
next, supplemented commercial ration was begun and this pro-
ceeded until the end of the experiment; Group Simultaneous –
commercial ration was offered during the ﬁrst 2 weeks of the
experiment; in the following 2 weeks, the animals received 4 doses
of DMH (20 mg/kg b.w., i.p.), where during the same time the ani-
mals were fed with commercial ration supplemented with A. blazei;
Group Post-treatment – for 4 weeks the animals were given com-
mercial ration, where in the 3rd and 4th weeks DMH was admin-
istered (20 mg/kg b.w., i.p.). After these 2 weeks, commercial
ration supplemented with A. blazei was offered for the last 72 h
of the experiment; Group pre-treatment + Continuous – commer-
cial ration supplemented with A. blazei was offered during the
whole experimental period, where in the 3rd and 4th weeks the
animals were given DMH (20 mg/kg b.w., i.p.), as in the protocol
described above, and supplementation proceeded up to the mo-
ment the animals were euthanized (Fig. 1).
2.3.2. Experiment 2
The experimental groups were the same as described in
Section 2.3.1. However, this experiment lasted 10 weeks longer
after the administration of the last dose of DMH. In this manner,
the time of supplementation in post-treatment and pre-
treatment + continuous were extended until the end of the
experimental period (Fig. 2).
2.4. Biological assays
2.4.1. Experiment 1
2.4.1.1. Comet assay. The comet assay was performed according to
Singh et al. (1988) and Tice (1995) with modiﬁcations. The slides
were prepared by depositing on a slide, previously coated with
Experiment 1 
Weeks 
0                                              2                                              4                                
6 
Control Group 
n=7 
DMH Group   
n=7
Agaricus blazei Group    
n=7 
Pre-treatment Group   
n=7
Simultaneous Group   
n=7 
 Post-treatment Group   
n=7 
Continuous Group   
n=7 
Legend:
 Commercial ration     
Filtered water  (v.o) 
            Commercial ration suplemmented with Agaricus blazei (10%) 
DMH 20mg/kg (i.p) 
EDTA (i.p) 
        T1- 24 hours after  the administration of the last dose of DMH 
        T2- 48 hours the administration of the last dose of DMH 
         T3- 72 hours the administration of the last dose of DMH 
Animals Sacrifice 
   n= number of animals per experimental group. 
Fig. 1.
Experiment 2 
Weeks 
0                      2                            4                                                                      14
Control Group 
n=11 
 DMH Group 
n=11 
Agaricus blazei Group 
n=11 
 Pre-treatment Group 
n=11 
Simultaneous Group 
n=11 
 Post-treatment Group 
n=11 
 Continuous Group   
n=11 
Legend: 
   Commercial ration    
   Commercial ration supplemented with Agaricus blazei (10%) 
DMH 20mg/kg (i.p)
EDTA (i.p) 
Animals sacrifice 
n= number of animals per experimental group. 
Fig. 2.
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last administration of DMH or its vehicle, with 120.0 lL LPM aga-
rose (1.5%), at 37 C. Next, the slides were covered with glass cov-erslip and chilled at 4 C for 20 min. After removal of the coverslips,
the slides were immersed in lysis solution, freshly prepared, com-
posed of 89.0 mL lysis stock solution (2.5 M NaCl, 100.0 mM EDTA,
P.L. Ishii et al. / Regulatory Toxicology and Pharmacology 59 (2011) 412–422 41510.0 mM Tris, pH 10.0 adjusted with solid NaOH, 890.0 mL of dis-
tilled water and 1% sodium lauryl sarcosinate), 1.0 of mL Triton
X-100 (Merck) and 10.0 mL of DMSO (dimethyl sulfoxide). Lysis
was allowed to proceed for 1 h, at 4 C, protected from light. Next,
the slides were placed in a electrophoresis chamber with pH > 13.0
solution (300.0 mM NaOH and 1.0 mM EDTA, prepared from a
stock solution of 10.0 N NaOH and 200.0 mM EDTA, pH 10.0) at
4 C for 20 min to denature DNA. Electrophoresis was carried out
at 25.0 V and 300.0 mA (1.25 V/cm). Afterward, the slides were
neutralized with 0.4 M Tris–HCl buffer, pH 7.5, for 3 cycles of
5 min, air-dried, ﬁxed in absolute ethanol for 10 min and saved
for later analysis. For staining, the slides were covered with
100.0 lL of ethidium bromide (20.0 lg/mL) and a coverslip. The
material was evaluated with a ﬂuorescence microscope (Bioval,
Model L 2000A) at 400 times magniﬁcation, with an excitation ﬁl-
ter of 420–490 nm and emission ﬁlter of 520 nm.
A total of 100 cells per treatment were analyzed visually, classi-
fying the comets as: class 0 – cells not damaged and that had no
tail; class 1 – cells with tail smaller than the diameter of the nu-
cleus; class 2 – cells with tail size between 1 and 2 times the diam-
eter of the nucleus; class 3 – cells with tail larger than 2 times the
diameter of the nucleus. Apoptotic cells, which showed a totally
fragmented nucleus, were not counted (Kobayashi et al., 1995).
The total score was calculated by summing the resulting values
of the multiplication of total number of cells observed in each class
of lesion by the value of the class (0–3). Statistical analysis was
performed by ANOVA followed by Tukey’s test (p < 0.05).
2.4.1.2. Differential blood cell counts. Peripheral blood was drawn
for differential cell counts at 24, 48 and 72 h after the last admin-
istration of EDTA and DMH. A caudal vein puncture was performed
and blood smears were made on slides. The slides were air-dried
and submitted to rapid staining using the Kit Panotico developed
by Laborclin Laboratory (Gurr, 1965, 1971).
Analysis of the slides was carried out with a light microscope
(Microscope DBG) at 1000 times magniﬁcation. A total of 100 cells
per animal were analyzed, in a blinded test, and differentiated as
lymphocytes, neutrophils, monocytes, eosinophils and basophils.
Statistical analysis was performed by ANOVA followed by
Tukey’s test (p < 0.05).
2.4.1.3. Phagocytic activity of spleen cells. At 72 h after the last appli-
cation of EDTA or DMH the animals were euthanized and the
spleens collected. These organs were cut into pieces with scissors
and then pressed through a stainless steel screen with 5 ml of ster-
ile phosphate buffer, Ca2+ and Mg+2 free, pH 7.4. Repeated pipetting
with a Pasteur pipet was used to obtain a homogeneous cell sus-
pension. One hundred microliters of cell suspension were placed
immediately in the center of a slide pre-coated with acridine or-
ange (1 mg/mL) and slide was then coverslipped. The slides were
stored in a freezer until time of analysis. The slides were viewed
with a ﬂuorescence microscope (Bioval, Model L 2000A) at 400
times magniﬁcation, with an excitation ﬁlter of 420–490 nm and
emission ﬁlter of 520 nm. A total of 200 cells/animal were ana-
lyzed, in a blinded test, in two categories: absence or presence of
phagocytosis based on the descriptions of Hayashi et al. (1990).
Statistical analysis was carried out using ANOVA and Tukey’s
test (p < 0.05).
2.5. Experiment 2
2.5.1. Assay for aberrant crypt foci – sampling, processing and analysis
of colon
After the period of 14 weeks of experiment, the mice were
euthanized by cervical dislocation, and an incision was then made
on the ventral side, along the medial line from the pubic region upto the xiphoid process. The muscles of the abdomen were retracted
laterally using incisions in the proximal and distal part. After local-
izing the proximal colon, a ligature was made with cotton thread.
Afterwards, the colon was removed, from the proximal part up to
the rectum, and washed with normal saline to remove the feces.
After washing, the colon was opened longitudinally along the bor-
der of the mesenteric insertion, stretched out on Styrofoam plates
and the ends ﬁxed with pins. The plates were immersed in a trough
with 10% buffered formalin, for at least 24 h. At the moment of
analysis, each segment of colon was stained with 10% methylene
blue for 10 min and then placed on a microscope slide, with the
mucosa side up, for analysis using a light microscope (Microscope
DBG) at 100 times magniﬁcation. All the mucosa was examined for
the identiﬁcation and quantiﬁcation of aberrant crypt foci based on
the criteria utilized by Bird (1987): (I) focus consisting of a single
crypt – the aberrant crypt shows lining by a think epithelial layer,
with elliptical luminal opening and larger in size (at least 2 times)
than the surrounding normal crypts; (II) focus with two or more
crypts – the aberrant crypts form distinct blocks and occupy an
area greater than that occupied by an equivalent number of crypts
of normal morphology, and there is no presence of normal crypts
separating the aberrant crypts within these foci.
The total number of aberrant crypt foci, total aberrant crypts
per foci and the ratio crypt/focus were compared among the differ-
ent treatments utilizing ANOVA followed by Tukey’s test, and the
differences were considered statistically signiﬁcant when p < 0.05.3. Results
3.1. Experiment 1
Table 1 presents themeans ± standarddeviation of the frequency
of lesioned cells, distribution among the classes of DNA damage and
scores with regard to the comet assay in peripheral blood cells of
mice. Statistical analysis demonstrated that there was no statisti-
cally signiﬁcant difference between the control group and that sup-
plementedwith themushroom, demonstrating the lack of genotoxic
activity. Themean number of lesioned cells in the control groupwas
11.86 ± 3.80 and in the group supplemented with the mushroom
12.29 ± 5.71. When comparing the DMH groups and those where
the drug was combined with the mushroom, antigenotoxic activity
could be observed for all protocols. The percent reduction in damage
was 24.24%, 38.76%, 45.52% and 50.09% for the treatment protocols
simultaneous, pre-treatment + continuous, pre-treatment andpost-
treatment, respectively.
Differential blood cell counts were determined at 24, 48 and
72 h after the last administration of DMH, and the values are pre-
sented in Tables 2–4, respectively.
At 24 h, there were no statistically signiﬁcant differences for
any cell type between the different experimental groups. However,
the number of monocytes was higher than reference values in all
groups. The highest percentages were found in the groups that re-
ceived DMH and/or A. blazei, and the percentages varied from
4.57% to 8.57% (reference values: 0.1–3.5%). Eosinophils were also
higher in those groups that were given DMH, and the mean per-
centages varied from 0.43% to 1.00% (reference values: 0–0.4%).
Basophil counts were increased only in the group that received
treatment with DMH, and the mean value was 0.57% (reference
values: 0–0.3%).
At 48 h, the lymphocyte, eosinophil and basophil counts did not
show statistically signiﬁcant differences. Lymphocytes were found
to be within the range of reference values (55–95%) and the mean
percentage varied from 63.86% to 70.28%. However, the number of
eosinophils was found to be above the reference values (0–0.4%) in
all experimental groups, and mean percentages varied from 0.57%
Table 1
Means ± standard deviation of the frequency of lesioned cells, distribution among the classes of DNA damage and scores with regard to the score in the tests for genotoxicity and
antigenotoxicity of A. blazei in the comet assay in peripheral blood of male mice:
Experimental groups Lesioned cells Damage classes Score
0 1 2 3
Genotoxicity
Control 11.86 ± 3.80a 89.00 ± 3.65 9.57 ± 3.05 2.14 ± 2.19 0.14 ± 0.38 14.28 ± 5.06a
DMH 83.71 ± 6.10d 15.71 ± 6.63 60.71 ± 12.94 14.86 ± 10.59 8.71 ± 4.11 116.57 ± 20.98d
Agaricus 12.29 ± 5.71ª 87.71 ± 5.71 11.43 ± 5.13 0.71 ± 1.11 0.14 ± 0.38 13.29 ± 6.77ª
Antigenotoxicity
Pre-treatment 51.00 ± 6.51b,c 48.86 ± 10.11 38.43 ± 8.42 8.86 ± 7.49 3.86 ± 4.26 67.71 ± 24.14b
Simultaneous 66.29 ± 11.78c 33.71 ± 11.77 39.00 ± 12.22 15.57 ± 6.50 11.71 ± 7.30 105.29 ± 25.57c,d
Post-treatment 47.14 ± 10.96b,c 52.43 ± 11.63 28.86 ± 3.24 16.00 ± 8.12 2.71 ± 1.50 69.00 ± 20.95b
Pre + Continuous 55.86 ± 14.04c 43.29 ± 14.02 34.29 ± 8.87 16.71 ± 6.16 4.86 ± 4.10 82.29 ± 25.81b,c
Control – negative control – EDTA 0.1 mL/10 g b.w. (body weight); DMH – DMH (dimethylhydrazine) 20 mg/kg b.w. (body weight) for 2 weeks (positive control); A. blazei –
A. blazei 10%/kg c.r. for 4 weeks; pre-treatment – A. blazei 10%/kg c.r. during the ﬁrst 2 weeks + DMH 20 mg/kg b.w. for 2 weeks; simultaneous – simultaneous treatment –
A. blazei 10%/kg c.r. + DMH 20 mg/kg b.w. for 2 weeks; post-treatment – DMH 20 mg/kg b.w. during the ﬁrst 2 weeks + A. blazei 10%/kg c.r. for 2 weeks; pre + continuous –
pre-treatment + continuous – A. blazei 10%/kg c.r. during the ﬁrst 2 weeks + A. blazei 10%/kg c.r.; DMH 20 mg/kg b.w. for 2 weeks. Different letters indicate statistically
signiﬁcant differences (p < 0.05; ANOVA/Tukey).
Table 2
Effects of supplementation of A. blazei on the blood cells 24 h.
Parameters Ref. val. Experimental groups
Control DMH Agaricus Pre Sim Post Pre + continuous
Lymphocyte 55–95% 65.71 ± 6.42a 70.28 ± 6.18a 65.86 ± 8.39a 66.28 ± 4.19a 63.86 ± 4.60a 67.43 ± 5.16a 63.86 ± 7.80a
Neutrophil 10–40% 29.86 ± 7.13a 21.71 ± 6.65a 27.86 ± 9.33a 26.28 ± 3.64a 26.68 ± 2.93a 27.14 ± 3.13a 27.57 ± 5.91a
Monocytes 0.1–3.5% 3.86 ± 1.57a 7.00 ± 2.31a 6.00 ± 4.55a 6.00 ± 2.45a 8.57 ± 2.99a 4.57 ± 2.99a 5.43 ± 2.30a
Eosinoﬁl 0–0.4% 0.14 ± 0.38a 0.43 ± 0.79a 0.28 ± 0.49a 0.43 ± 0.53a 1.00 ± 1.15a 0.71 ± 0.75a 0.71 ± 0.95a
Basophil 0–0.3% 0.14 ± 0.38a 0.57 ± 0.97a 0.00 ± 0.00a 0.14 ± 0.38a 0.14 ± 0.38a 0.28 ± 0.49a 0.28 ± 0.49a
Ref. val – reference values; control – negative control – EDTA 0.1 mL/10 g b.w.; DMH – DMH (dimethylhydrazine) 20 mg/kg b.w. for 2 weeks (positive control); A.
blazei – A. blazei 10%/kg c.r. for 4 weeks; Pre-treatment – A. blazei 10%/kg c.r. during the ﬁrst 2 weeks + DMH 20 mg/kg b.w. for 2 weeks; simultaneous – simultaneous
treatment – A. blazei 10%/kg c.r. + DMH 20 mg/kg b.w. for 2 weeks; post-treatment – DMH 20 mg/kg b.w. during the ﬁrst 2 weeks + A. blazei 10%/kg c.r. for 2 weeks;
pre + continuous – pre-treatment + continuous – A. blazei 10%/kg c.r. during the ﬁrst 2 weeks + A. blazei 10%/kg c.r.; DMH 20 mg/kg b.w. for 2 weeks. Different letters indicate
statistically signiﬁcant differences (p < 0.05; ANOVA/Tukey).
Table 3
Effects of supplementation of A. blazei on the blood cells 48 h:
Parameters Ref. val. Experimental groups
Control DMH Agaricus Pre Sim Post Pre + continuous
Lymphocyte 55–95% 78.00 ± 2.00a 80.00 ± 2.00a 72.57 ± 7.63a 70.71 ± 4.07a 72.43 ± 9.02a 74.28 ± 8.54a 71.14 ± 3.34a
Neutrophil 10–40% 21.57 ± 6.60a 13.43 ± 3.55b 24.28 ± 7.41a.b 23.71 ± 4.78a.b 20.43 ± 6.95a 21.00 ± 7.02a 21.00 ± 3.87a
Monocytes 0.1–3.5% 6.71 ± 2.43a 6.00 ± 1.82a 2.42 ± 1.62b 4.86 ± 2.12a.b 6.14 ± 1.95a 2.14 ± 1.21b 6.86 ± 1.68a
Eosinoﬁl 0–0.4% 1.00 ± 1.15a 2.28 ± 1.89a 0.57 ± 0.53a 0.57 ± 0.78a 0.85 ± 1.07a 0.86 ± 1.86a 0.71 ± 0.95a
Basophil 0–0.3% 0.14 ± 0.38a 0.43 ± 1.13a 0.14 ± 0.38a 0.00 ± 0.00a 0.14 ± 0.38a 0.14 ± 0.38a 0.28 ± 0.49a
Ref. val – reference values; control – negative control – EDTA 0.1 mL/10 g b.w.; DMH – DMH (dimethylhydrazine) 20 mg/kg b.w. for 2 weeks (positive control); A. blazei – A.
blazei 10%/kg c.r. for 4 weeks; Pre-treatment – A. blazei 10%/kg c.r. during the ﬁrst 2 weeks + DMH 20 mg/kg b.w. for 2 weeks; simultaneous – simultaneous treatment –
A. blazei 10%/kg c.r. + DMH 20 mg/kg b.w. for 2 weeks; post-treatment – DMH 20 mg/kg b.w. during the ﬁrst 2 weeks + A. blazei 10%/kg c.r. for 2 weeks; pre + continuous –
pre-treatment + continuous – A. blazei 10%/kg c.r. during the ﬁrst 2 weeks + A. blazei 10%/kg c.r.; DMH 20 mg/kg b.w. for 2 weeks. Different letters indicate statistically
signiﬁcant differences (p < 0.05; ANOVA/Tukey).
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with DMH, where the mean percentage was 0.43% (reference val-
ues: 0–0.3%). The neutrophil counts were found to be within the
range of reference values (10–40%) for all groups. However, the
DMH group showed a statistically signiﬁcant decline for this cell
type in relation to the other groups. When evaluating the mono-
cytes, it was possible to see that only the groups supplemented
with A. blazei and the post-treatment group showed mean percent-
ages of 2.42% and 2.14%, respectively, thus within the reference
values (0.1–3.5%). However, the other groups showed means above
the reference values, with statistically signiﬁcant differences.
At 72-h evaluation, lymphocytes and neutrophils were found to
be inside the range of reference values (lymphocytes: 55–95%;
neutrophils: 10–40%), and the mean percentages varied from
63.43% to 79.43% and 12.86% to 28.57%, respectively. Thelymphocytes did not show any signiﬁcant variation. The neutro-
phils decreased signiﬁcantly in number in the group that received
DMH, in relation to other groups, while the groups that received
DMH and A. blazei, except for the post-treatment protocol, showed
a tendency for a reduction in this cell type. In relation to the mono-
cytes, all groups showed numbers above the reference values with
exception of groups A. blazei and post-treatment, where these two
groups also showed statistically signiﬁcant differences in relation
to the others. The group that showed the highest mean percentage
was the one given supplementation with A. blazei in the pre-
treatment + continuous protocol, and the mean percentage of this
group was 6.00% (reference values: 0.1–3.5%). Eosinophils and
basophils did not show statistically signiﬁcant differences. How-
ever, eosinophil count was increased in all experimental groups
when compared to the reference values (0–0.4%), and the mean
Table 4
Effects of supplementation of A. blazei on the blood cells 72 h:
Parameters Ref. val. Experimental groups
Control DMH Agaricus Pre Sim Post Pre + continuous
Lymphocyte 55–95% 66.28 ± 9.94a 79.43 ± 5.32a 73.28 ± 8.79a 75.43 ± 8.60a 72.43 ± 6.24a 71.85 ± 10.68a 63.43 ± 13.02a,b
Neutrophil 10–40% 28.57 ± 9.20a 12.86 ± 4.41b 23.57 ± 8.52a,b 19.00 ± 9.90a,b 21.43 ± 3.91a,b 26.14 ± 11.00a,b 28.57 ± 13.43a
Monocytes 0.1–3.5% 3.71 ± 4.07a,b 3.57 ± 2.07a,b 1.71 ± 0.95a 4.43 ± 2.44a,b 4.57 ± 2.07a,b 1.57 ± 1.40a 6.00 ± 3.00b
Eosinoﬁl 0–0.4% 1.14 ± 0.90a 2.14 ± 1.21a 1.00 ± 0.82a 1.29 ± 1.11a 1.00 ± 1.15a 0.43 ± 0.53a 1.57 ± 1.98a
Basophil 0–0.3% 0.29 ± 1.76a 1.00 ± 1.15a 0.43 ± 0.79a 0.29 ± 0.49a 0.71 ± 0.95a 0.43 ± 0.79a 0.43 ± 0.53a
Ref. val – reference values; control – negative control – EDTA 0.1 mL/10 g b.w.; DMH – DMH (dimethylhydrazine) 20 mg/kg b.w. for 2 weeks (positive control); A. blazei – A.
blazei 10%/kg c.r. for 4 weeks; pre-treatment – A. blazei 10%/kg c.r. during the ﬁrst 2 weeks + DMH 20 mg/kg b.w. for 2 weeks; simultaneous – simultaneous treatment – A.
blazei 10%/kg c.r. + DMH 20 mg/kg b.w. for 2 weeks; post-treatment – DMH 20 mg/kg b.w. during the ﬁrst 2 weeks + A. blazei 10%/kg c.r. for 2 weeks; pre + continuous – pre-
treatment + Continuous – A. blazei 10%/kg c.r. during the ﬁrst 2 weeks + A. blazei 10%/kg c.r.; DMH 20 mg/kg b.w. for 2 weeks. Different letters indicate statistically signiﬁcant
differences (p < 0.05; ANOVA/Tukey).
Table 6
Mean values for initial weight, ﬁnal weight and weight gain of the animals during the
experimental period:
Experimental groups Initial weight (g) Final weight (g) Weight gain(g)
Control 37.64 ± 3.98a 43.45 ± 4.66a,b 5.82 ± 3.63b
DMH 36.91 ± 3.27a 43.09 ± 4.32a,b 6.18 ± 2.75b
Agaricus 47.09 ± 4.93b 42.73 ± 3.50a,b 4.36 ± 1.96a
Pre-treatment 46.55 ± 6.93b 49.27 ± 5.00c 2.73 ± 4.13b
Simultaneous 42.91 ± 5.39a,b 47.73 ± 4.82b,c 4.82 ± 2.40b
Post-treatment 49.09 ± 5.01b 45.82 ± 3.63b,c 3.27 ± 3.00a
Pre + continuous 45.09 ± 4.32b 36.64 ± 2.66a 5.45 ± 3.24a
g – gram; control – negative control – EDTA 0.1 mL/10 g b.w. for 2 weeks; DMH –
DMH (dimethylhydrazine) 20 mg/kg b.w. for 2 weeks (positive control); Agaricus –
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the control and pre-treatment groups did not show values greater
than the reference values (0–0.3%). In the other groups, the mean
percentage varied from 0.43% to 1.00%.
Table 5 presents the values referring to phagocytic activity in
the spleen. Statistical analysis indicated a difference between the
groups. The greatest indication of phagocytic activity appeared in
the groups with the pre-treatment + continuous, pre-treatment
and simultaneous protocols. The control, A. blazei and post-
treatment groups had similar activities but differed from the
groups mentioned above. The group treated only with DMH
showed the least phagocytic activity in spleen cells.A. blazei 10%/kg c.r. for 14 weeks; pre-treatment – A. blazei 10%/kg c.r. for
2 weeks + DMH 20 mg/kg b.w. for 2 weeks; simultaneous – simultaneous treatment
– A. blazei 10%/kg c.r. for 2 weeks + DMH 20 mg/kg b.w. for 2 weeks; post-treatment
– DMH 20 mg/kg b.w. for 2 weeks + A. blazei 10%/kg c.r. for 10 weeks; pre +
conitnuous – pre-treatment + continuous – A. blazei 10%/kg c.r. for 14 weeks + DMH
20 mg/kg b.w. for 2 weeks. Different letters indicate statistically signiﬁcant differ-
ences (p < 0.05; ANOVA/Tukey).3.2. Experiment 2
Table 6 presents the mean values for initial weight, ﬁnal weight
and weight gain of the animals. There was a statistical difference
among initial weights, varying between 36.91 ± 3.27 g and 49.09 ±
5.01 g, and among ﬁnal weights, with a variation of 36.64 ± 2.66 g
to 49.27 ± 5.00 g. The variation in weight gain was from 5.45 ±
3.24 g to 6.18 ± 2.75 g, which was statistically different. There
was weight loss in animals of the groups Agaricus, post-treatment
and pre-treatment + continuous, and weight gain in other groups,
where the pre-treatment group showed the least weight gain.
Table 7 lists the mean absolute and relative weights of the ani-
mals. In relation to absolute weights, that of liver showed a statisti-
cally signiﬁcant difference between the pre-treatment + continuous
group, having the lowestmean, and the control and Agaricus groups.
The relative weights of heart and liver differed statistically among
the groups. The groups DMH and post-treatment had the lowest
means for relativeweight of heart, and the pre-treatment + continu-
ous group the highest. In relation to relative weight of liver, the
groups simultaneous and post-treatment showed the lowest values,Table 5
Effects of supplementation of A. blazei on the frequency of splenic phagocytosis:
Experimental groups No. cells analyzed Total cells without evidence of
No. Abs. Mean ± SD
Control 1400 425 63.28 ± 5.41c
DMH 1400 516 63.71 ± 4.89d
Agaricus 1400 416 54.43 ± 4.04c
Pre 1400 348 49.71 ± 5.99a
Sim 1400 317 45.28 ± 6.52a
Post 1400 443 60.71 ± 6.42c
Pre + continuous 1400 226 32.28 ± 4.75b
Control – negative control – EDTA 0.1 mL/10 g b.w.; DMH – DMH (dimethylhydrazine) 20
pre-treatment – A. blazei 10%/kg c.r. during the ﬁrst 2 weeks + DMH 20 mg/kg b.w. for 2 w
kg b.w. for 2 weeks; post-treatment – DMH 20 mg/kg b.w. during the ﬁrst 2 weeks + A. bla
10%/kg c.r. during the ﬁrst 2 weeks + A. blazei 10%/kg c.r.; DMH 20 mg/kg b.w. for 2 wee
Tukey).and the Agaricus group the highest mean. With regard to the means
for the other organs, the means of the relative and absolute weights
did not show statistically signiﬁcant differences.
The number, distribution and reduction in damage with regard
to aberrant crypt foci in the colon of the animals are shown in
Table 8. The control group did not show aberrant crypt foci. The
Agaricus group, despite showing a focus of two crypts resembled
the control group statistically. Statistical analyses indicated the
anticarcinogenic activity of the A. blazei group in relation to the
pre-treatment and pre-treatment + continuous groups with a per-
cent reduction in damage of 54.60% and 50.45%, respectively. The
groups simultaneous and post-treatment showed numerous inter-
mediates of aberrant crypt foci in comparison to the groups de-
scribed above and the control groups. Thus, it was shown thatphagocytosis Total cells with evidence of phagocytosis
Percentage No. abs. Mean ± SD Percentage
31.64 975 139.28 ± 6.42c 69.65
36.85 884 126.28 ± 4.89d 63.15
29.71 984 140.57 ± 4.04c 70.29
24.85 1052 150.28 ± 5.99a 75.15
22.64 1083 154.71 ± 6.52a 77.36
30.35 957 136.71 ± 5.41c 68.35
16.14 1174 167.71 ± 4.75b 83.86
mg/kg b.w. for 2 weeks (positive control); A. blazei – A. blazei 10%/kg c.r. for 4 weeks;
eeks; simultaneous – simultaneous treatment – A. blazei 10%/kg c.r. + DMH 20 mg/
zei 10%/kg c.r. for 2 weeks; pre + continuous – pre-treatment + continuous – A. blazei
ks. Different letters indicate statistically signiﬁcant differences (p < 0.05; ANOVA/
Table 7
Mean values of absolute and relative weights With regard to the means for the other organs of the animals after of experimentation period:
Experimental
groups
Total weight (g) Relative weight (g)
Heart Lung Liver Kidneys Heart Lung Liver Kidneys
Control 0.2407 ± 0.0322a 0.2531 ± 0.0457a 2.2720 ± 0.3219b 0.6670 ± 0.1072a 0.0056 ± 0.0009a,b 0.0058 ± 0.0010a 0.0524 ± 0.0066b,c 0.0155 ± 0.0028a
DMH 0.2289 ± 0.0363a 0.2569 ± 0.0498a 2.0627 ± 0.2858a,b 0.6587 ± 0.0977a 0.0054 ± 0.0010a 0.0060 ± 0.0011a 0.0479 ± 0.0053a,b,c 0.0154 ± 0.0024a
Agaricus 0.2703 ± 0.0429a 0.2976 ± 0.1263a 2.2738 ± 0.3554b 0.6700 ± 0.1325a 0.0064 ± 0.0011a,b 0.0070 ± 0.0028a 0.0531 ± 0.0058c 0.0157 ± 0.0028a
Pre-
treatment
0.2816 ± 0.0618a 0.2809 ± 0.0433a 2.2898 ± 0.2439b 0.6991 ± 0.1213a 0.0057 ± 0.0010a,b 0.0057 ± 0.0010a 0.0466 ± 0.0041a,b 0.0141 ± 0.0014a
Simultaneous 0.2736 ± 0.0343a 0.2711 ± 0.0573a 2.1710 ± 0.1761a,b 0.6595 ± 0.0729a 0.0057 ± 0.0008a,b 0.0057 ± 0.0012a 0.0457 ± 0.0038a 0.0138 ± 0.0008a
Post-
treatment
0.2416 ± 0.0526a 0.2547 ± 0.0322a 2.0183 ± 0.2165a,b 0.6170 ± 0.0791a 0.0053 ± 0.0010a 0.0055 ± 0.0004a 0.0441 ± 0.0037a 0.0135 ± 0.0012a
Pre +
continuous
0.2712 ± 0.0520a 0.2492 ± 0.0443a 1.9130 ± 0.1803a 0.5822 ± 0.0641a 0.0069 ± 0.0010b 0.0063 ± 0.0010a 0.0483 ± 0.0037a,b 0.0147 ± 0.0013a
g – gram; control – negative control – EDTA 0.1 mL/10 g b.w. for 2 weeks; DMH – DMH (dimethylhydrazine) 20 mg/kg b.w. for 2 weeks (positive control); Agaricus – A. blazei
10%/kg c.r. for 14 weeks; pre-treatment – A. blazei 10%/kg c.r. for 2 weeks + DMH 20 mg/kg b.w. for 2 weeks; simultaneous – simultaneous treatment – A. blazei 10%/kg c.r. for
2 weeks + DMH 20 mg/kg b.w. for 2 weeks; post-treatment – DMH 20 mg/kg b.w. for 2 weeks + A. blazei 10%/kg c.r. for 10 weeks; pre + conitnuous – pre-treatment + con-
tinuous – A. blazei 10%/kg c.r. for 14 weeks + DMH 20 mg/kg b.w. for 2 weeks. Different letters indicate statistically signiﬁcant differences (p < 0.05; ANOVA/Tukey).
Table 8
Number, distribution and reduction in damage with regard to aberrant crypt foci (ACF) in the colon of male mice.
Treatment Total of ACF %RD Total of AC Absolute Values of AC/Foci Relation AC/Foci
Absolute Values Mean ± EPM 1AC/Foci 2AC/Foci 3AC/Foci 4AC/Foci
Carcinogenicity
Control 0 0,00 ± 0,00a - 0 0 0,00 0,00 0,00 0,00
DMH 337 30,64 ± 6,52c - 639 137 117 64 19 1.90
Agaricus 1 0,09 ± 0,30a - 2 0,00 1,00 0,00 0,00 2,00
Anticarcinogenicity
Pre-treatment 153 13,91 ± 2,59a,b 54,60 307 55 54 32 12 2,01
Simultaneous 172 15,64 ± 2,73b,c 48,96 368 48 64 48 12 2,14
Post-treatment 234 21,27 ± 4,25b,c 30,56 458 90 82 44 18 1,96
Pre + Continuous 167 15,18 ± 2,36b 50,45 322 62 62 32 11 1,93
Legend: Control – Negative control – EDTA 0,1mL/10 g b.w. (body weight); DMH – DMH (dimethylhydrazine) 20 mg/Kg b.w. (body weight) for 2 weeks (positive control);
Agaricus blazei – Agaricus blazei 10%/Kg c.r. (commercial ration) for 4 weeks; Pre-treatment – Agaricus blazei 10%/Kg c.r. (commercial ration) during the ﬁrst 2 weeks + DMH
20 mg/Kg b.w. (body weight) for 2 weeks; Simultaneous - Simultaneous treatment – Agaricus blazei 10%/Kg c.r. (commercial ration) + DMH 20 mg/Kg b.w. (body weight) for
2 weeks; Post-treatment – DMH 20 mg/Kg b.w. (body weight) during the ﬁrst 2 weeks + Agaricus blazei 10%/Kg c.r. (commercial ration) for two weeks; Pre + Continuous -
Pre-treatment + Continuous – Agaricus blazei 10%/Kg c.r. (commercial ration) during the ﬁrst 2 weeks + Agaricus blazei 10%/Kg c.r. (commercial ration); DMH 20 mg/Kg b.w.
(body weight) for 2 weeks. Different letters indicate statistically signiﬁcant differences (p < 0,05; ANOVA/Tukey).
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percent reduction in damage indicates a tendency toward preven-
tion, where the percentages of prevention of foci were 48.96% for
the simultaneous group and 30.56% for the post-treatment group.
4. Discussion
Various important substances with immunomodulatory (Kent-
aro et al., 2007; Kawamura et al., 2005; Akramiene˙ et al., 2007)
and antitumor activity (Firenzuoli et al., 2007; Talcott et al.,
2007; Murakawa et al., 2007) were isolated from mushrooms,
among which the polysaccharides stand out, particularly b-D-
glucans, polysaccharopeptides, polysaccharide proteins and pro-
teins. Also possessing these activities are triterpenes, lipids and
phenols (Angeli et al., 2008).
In view of the known properties of mushrooms as functional
foods, and due to their constituents and the use of A. blazei on a
large scale in different population groups for treating cancer and
enhancing the immune system, the present study evaluated the
supplementation of this mushroom in the normal diet of mice, at
a proportion of 10%, by means of the comet assay, aberrant crypt
foci assay, differential cell counts in peripheral blood and splenic
phagocytic activity.In light of the results obtained, it appears that supplementation
with A. blazei did not show genotoxic activity, and this ﬁnding al-
lows us to infer that supplementation with this mushroom, based
on this protocol, does not produce DNA damage that leads to the
development of cancer. This ﬁnding is supported by the studies
of Menoli et al. (2001), Delmanto et al. (2001), Oliveira et al.
(2002), Bellini et al. (2003), Luiz et al. (2003), Guterrez et al.
(2004), Machado et al. (2005) and Guterres et al. (2005), who re-
ported that the administration of A. blazei, in different forms of ex-
tract and concentrations, did not produce genotoxic and/or
mutagenic activity.
Other authors reported that A. blazei and b-glucan possess anti-
genotoxic activity (Chorvatovicová et al., 1999; Guterrez et al.,
2004; Guterres et al., 2005; Angeli et al., 2008; Bellini et al.,
2006). In the present study, this property was demonstrated for
daily supplementation with 10% A. blazei in the normal diet. How-
ever, some authors such as Oliveira et al. (2007) report the lack of
antigenotoxic activity with the administration of b-glucans iso-
lated from Saccharomyces cerevisiae in Chinese hamster ovarian
cells. Similarly, Oliveira et al. (2002) conducted a study with aque-
ous extract of A. blazei in mice, and demonstrated the lack of anti-
genotoxicity using the comet assay. Thus, the literature shows that
there is the results of the various studies are not consistent with
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responses vary based on the protocols, doses and types of extracts
or forms of treatments utilized.
When the comet data are correlated with the splenic phagocy-
tosis ﬁndings, it can be seen that the frequency of phagocytosis is
similar in the control, A. blazei and post-treatment groups. This fact
suggests that the administration of mushroom probably does not
increase the phagocytosis in the spleen in animals suffered no
damage in the genetic material contained which could be visual-
ized by means of the comet assay. Thus, supplementation with A.
blazei could be correlated with an increase in monocytes and later
macrophages. However, these become active and participate in
phagocytosis only when need be. In case the body does not need
this function, these cells remain present, but without exerting
any phagocytic activity.
When evaluating the group that received DMH and those sub-
mitted to the protocols of pre-treatment, simultaneous, post-
treatment and pre-treatment + continuous, it is seen that the
frequency of lesioned cells observed by the comet test in these
groups is better than that shown by the DMH group. An analysis
of splenic phagocytosis for these same groups demonstrates that
greater phagocytic capacity is found in the protocols of pre-treat-
ment, simultaneous and pre-treatment + continuous and that the
values found in the DMH group are lower in comparison with all
the groups. This suggests that supplementation with A. blazei in a
protocol of pre-treatment (2 weeks), simultaneous treatment
(2 weeks) or pre-treatment + continuous (4 weeks) is capable of
modulating phagocytic activity in spleen cells, and it appears that
the longer the time of provision of supplemented ration, the better
the efﬁcacy of the spleen is to remove cells in the blood stream that
have some type of genetic alteration and that could contribute
indirectly to the development of cancer. However, this assay and
the results presented here can help in understanding what could
occur in cells of non-hematopoeitic tissues, since the metabolites
of DMH reach all cell types and different tissues of the body. Thus,
in analyzing the phagocytosis data, it can be seen that actually the
increase in time of supplementation is related to an improvement
in phagocytic capacity, in a statistically signiﬁcant manner, and
that this supplementation alone is not related to any damage
observed in the animals, be it by the comet assay or by the
demonstration of phagocytic activity.
These notions are reinforced by data from the analysis of differ-
ential blood cell counts, which demonstrated that at 24 h the num-
ber of monocytes in all the groups are above the reference value.
This is especially notable in the groups DMH, A. blazei, pre-
treatment, simultaneous and pre-treatment + continuous. As dis-
cussed earlier, the lack of elevation in monocyte counts in the
post-treatment protocol is due to the short time of supplementa-
tion with mushroom. In analyzing the other groups, it can be
inferred that the administration of DMH is capable of producing
a picture of monocytosis, because of the inﬂammatory reaction
that the drug causes, especially in the intestinal mucosa of mice
(Wiebecke et al., 1973; Richards, 1977; Deschner, 1978; Wargovich
et al., 1983; Krutovskikh and Turosov, 1994; Bain, 2007).
Another fact is that even without suffering injury the group that
received only A. blazei also showed a picture of monocytosis. This
could indicate that the supplementation of the diet with this
mushroom modulates the immune system, making it more efﬁ-
cient with regard to phagocytic function, since monocytes in the
blood represent a maturation phase of phagocytic mononuclear
cells originating in the bone marrow. These cells enter the blood
stream, where they remain only a few days, and by passing
through the walls of the capillaries and venules, they penetrate
some organs, including the spleen, transforming into macrophages
which constitute a more advanced phase in the life of phagocytic
mononuclear cells (Junqueira and Carneiro, 2008).On the other hand, when the groups that received DMH com-
bined with supplementation with A. blazei are evaluated, there
was an even greater increase in the presence of circulating mono-
cytes, except for the pre-treatment + continuous group. This ﬁnd-
ing suggests that in these groups there was a better splenic
phagocytic capacity, since these monocytes can be found in the
spleen in the form of macrophages at a later time. When evaluating
phagocytosis in the spleen, this notion is conﬁrmed, since this
parameter was increased in these groups. Another fact that is
called to our attention is that the pre-treatment + continuous
group did not show such a marked increase in monocytes, when
compared to the pre-treatment and simultaneous groups, because
these monocytes could have already migrated to the spleen, which
is corroborated by higher phagocytic activity found in this group.
In the evaluations at 48 and 72 h, monocytosis was found for all
the groups except the A. blazei and post-treatment groups. The lack
of monocytosis in the A. blazei group could be better understood
when considering that these circulating cells migrate to other tis-
sues that are not hematopoietic where the spleen is also consid-
ered among these. However, as these animals were not
undergoing any process of injury, the technique of phagocytosis
in the spleen did not demonstrate their effective presence, that
is, resulting in phagocytosis. With respect to the lack of monocyto-
sis in post-treatment at 48 and 72 h, where the mean values were
always lower than those shown by the controls, albeit not statisti-
cally signiﬁcant, it is possible that the short time of supplementa-
tion was not sufﬁcient to modulate the immune system of the
experimental animals.
The maintenance of monocytosis in the pre-treatment, simulta-
neous and pre-treatment + continuous groups could be explained
by the fact that A. blazei is capable of modulating the immune sys-
tem, so that the cells with genetic damage are sequestered by the
spleen, thereby diminishing indirectly the maintenance of cells
that could be initiated for the development of cancer in the body.
The results obtained are in accordance with those reported by
Alves de Lima (2006) who demonstrated that supplementation
with b-glucan was related to an increase in monocytes in periphe-
ral blood and granulocyte progenitor cells both in spleen and bone
marrow. These authors also considered that the macrophages are
phagocytes and that their function is to remove foreign bodies,
parasites and bacteria. Thus, it is assumed that reducing the fre-
quency of micronuclei in reticulocytes of peripheral blood may
be due to the improvement of phagocytic activity in spleen cells.
It was from these considerations, the authors of this research were
also the inferences made earlier.
However, despite these various considerations with respect to
the biological activities favored by supplementation with A. blazei,
which can be related indirectly to the prevention of cancer, the
present research group evaluated another technique that can help
even more in understanding the actual effectiveness of this supple-
mentation in controlling pre-malignant lesions. These can be bet-
ter in demonstrating the anticarcinogenic capacity of the
mushroom in study. The assay in question was the aberrant crypt
foci assay, which is a validated and common experimental model
for determining the macro–microscopic and clinical behavior of
pre-neoplastic lesions, where the results can be applied to humans,
because these lesions are the ﬁrst to appear in the carcinogenesis
of the colon in both rodents and humans (Druckrey et al., 1978;
Bird, 1995; Banerjee et al., 1998).
Thus, this study also demonstrated the efﬁcacy of the mush-
room A. blazei in preventing carcinogenesis induced by DMH. In ro-
dents, the administration of DMH leads to a slight inﬂammatory
reaction and an increase in cell proliferation in the mucosa of the
colon (Krutovskikh and Turosov, 1994). Its successive application
results in continuous proliferation, producing an increase in the
number of cells in the DNA synthesis phase (Deschner, 1978;
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the crypts and hypertrophy of the mucosa (Wiebecke et al.,
1973; Richards, 1977).
Different treatment protocols need to be studied to elucidate
the mode of action of biological molecules or chemical compounds
in antimutagenesis (Ferguson, 1994; Flagg et al., 1995; Antunes,
2000; De Flora and Ferguson, 2005; Oliveira et al., 2006, 2007).
Therefore, in this study, male mice were exposed to DMH and
b-glucan, utilizing the protocols of pre-treatment and post-treat-
ment which can indicate a bioantimutagenic action, and the proto-
col of simultaneous treatment which can indicate desmutagenic
and bioantimutagenic activities, in addition to the continuous
treatment protocol (Morita et al., 1978; Kada, 1983; Ferguson,
1994; Flagg et al., 1995; Antunes, 2000; Oliveira et al., 2002; De
Flora and Ferguson, 2005; Oliveira et al., 2006, 2007).
The pre-treatment group showed a percent reduction in
damage of 54.60%. In the pre-treatment + continuous group there
was a reduction of 50.45% in the incidence pre-neoplastic damage,
demonstrating that the mushroom acts in a chemopreventive
manner. The simultaneous and post-treatment groups showed a
low rate of prevention of aberrant crypt foci. These data suggest
that the mushroom act through bioantimutagenesis as well as
desmutagenesis. However, it appears that the least effective action
is through desmutagenesis, as suggested by the poor prevention of
lesions in simultaneous treatment. This ﬁnding can be reinforced
by the percent reduction in damage shown by at least the comet
assay.
Bobek et al. (1998, 2001), Bobek and Galbavy (2001) and
Nosál’ová et al. (2001) tested Pleurotus ostreatus in rats and
observed a signiﬁcant reduction in aberrant crypt foci, demonstrat-
ing the anticarcinogenic activity of this edible mushroom. In these
studies, the authors used pre-treatment + continuous protocols,
and their results also suggest effects involving desmutagenesis
and bioantimutagenesis.
The decrease in the aberrant crypt foci can be explained by the
soluble ﬁbers acting as a selective substrate for bacteria that pro-
duce short-chain fatty acids such as butyrate which appears to
be capable of promoting apoptosis in the human intestine, main-
taining the tissue in a good state (Hague et al., 1993; Scheppach
et al., 1995; Green et al., 1998). In addition, these ﬁbers increase
the number of biﬁdobacteria which produce little or no b-glucu-
ronidase, an enzyme that decreases the metabolism of DMH and
consequently diminishes carcinogenicity in the colorectal mucosa
(Hauly and Moscatto, 2002) and other damage which can be visu-
alized by other techniques in the peripheral blood and spleen, such
as in the case of the comet assay and splenic phagocytosis assay,
respectively, for example. These bacteria even produce lactic acid
which decreases intestinal pH, and consequently generates a bac-
tericidal medium for putrefactive bacteria, besides reducing the
absorption of ammonia (Goldin and Gorbach, 1980; Koo and Rao,
1991; Gibson and Macfarlane, 1995).
Another possible mechanism of anticarcinogenic action is the
reduction in carcinogenic substances, due to their adsorption to
the cell wall of microbiota. The microbiota can even retain water
causing increased intestinal transit, thereby diluting all the compo-
nentspresent in thecolon. In thismanner, thereare inhibitoryeffects
in the stages of initiation and promotion of colon cancer (Reddy
and Rivenson, 1993; Hague et al., 1993; Pool-Zobel et al., 1993;
Scheppach et al., 1995; Pierre et al., 1997; Peridgon et al., 1998).
The literature even shows various other works that correlate
the data here discussed, such as the recent study by Lin et al.
(2004) These authors reported that a fraction of maitake, an extract
isolated from the mushroom Grifola frondosa, in which the isolated
active component is b-glucan, caused an improvement in colony
formation of granulocytes/macrophages, improved response of
progenitor cells in bone marrow and better recovery of granulo-cytes/macrophages in response to the administration of doxorubi-
cin which causes bone marrow suppression and also increases the
incidence of micronuclei in different tissues.
Rodrigues et al. (2003) demonstrated that the active principle of
A. blazei produces immunomodulatory effects, namely the activa-
tion of macrophages and neutrophils, which cause tumor regres-
sion. Mizuno et al. (1998) demonstrated the stimulation of
lymphocytes in mice treated with polysaccharides from A. blazei,
suggesting that this mushroom could be an effective prophylactic,
reducing the occurrence of cancer by increasing the production of
lymphocytes. Chan et al. (2007) concluded that A. blazei causes a
signiﬁcant increase in phagocytic activity in rats, where seven
parameters were tested and shown to improve in animals supple-
mented with A. blazei, demonstrating the appreciable capacity of
this mushroom to modulate the function of the immune system
in the animals evaluated and conﬁrming its immunomodulating
potential, as discussed here also.
In a clinical study carried out in human volunteers, the authors
conﬁrmed that A. blazei can help in alleviating symptoms related to
diseases like obesity, hypertension, diabetes and cancer through its
antiinﬂammatory and antitumor effects and its stimulation of the
immune system (Liu et al., 2008).
Based on these considerations, A. blazei could act as an immuno-
modulatory food and be effective in improving phagocytic activity
in the spleen. These facts suggest a mechanism for eliminating cells
with DNA damage (genotoxic and mutagenic) related to the devel-
opment of cancer. Finally, the ﬁndings suggest that mushroom has
a true efﬁcacy in preventing colorectal carcinogenesis, also through
the capacity of modulating the intestinal microbiota responsible
for the degradation of pro-carcinogens. However, further studies
are needed to elucidate the mechanisms underlying the anticarci-
nogenicity of A. blazei, so that it can be better indicated as an
immunomodulatory food and a chemopreventive agent effective
in protecting against colorectal cancer.Conﬂict of interest statement
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